S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
294. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of
patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Journal of Urology 2003;169(3):849-54. http://www.ncbi.nlm.nih.gov/pubmed/12576797
295. Catalona WJ, Miller DR, Kavoussi LR. Intermediate-term survival results in clinically
understaged prostate cancer patients following radical prostatectomy. Journal of Urology
1988;140(3):540-3. http://www.ncbi.nlm.nih.gov/pubmed/3411669
296. Aristizabal SA, Steinbronn D, Heusinkveld RS. External beam radiotherapy in cancer of the
prostate. The University of Arizona experience. Radiother Oncol 1984;1(4):309-15.
http://www.ncbi.nlm.nih.gov/pubmed/6505267
297. Bagshaw MA, Pistenma DA, Ray GR, Freiha FS, Kempson RL. Evaluation of extended-field
radiotherapy for prostatic neoplasm: 1976 progress report. Cancer Treat Rep
1977;61(2):297-306. http://www.ncbi.nlm.nih.gov/pubmed/872133
298. Higgins GS, McLaren DB, Kerr GR, Elliott T, Howard GC. Outcome analysis of 300 prostate
cancer patients treated with neoadjuvant androgen deprivation and hypofractionated
radiotherapy. Int J Radiat Oncol Biol Phys 2006;65(4):982-9.
http://www.ncbi.nlm.nih.gov/pubmed/16750310
299. Liu M, Pickles T, Agranovich A, Berthelet E, Duncan G, Keyes M, Kwan W, McKenzie M,
Morris J, Pai H, Tyldesley S, Wu J. Impact of neoadjuvant androgen ablation and other
factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol
Phys 2004;58(1):59-67. http://www.ncbi.nlm.nih.gov/pubmed/14697421
300. McGowan DG. The value of extended field radiation therapy in carcinoma of the prostate.
Int J Radiat Oncol Biol Phys 1981;7(10):1333-9.
http://www.ncbi.nlm.nih.gov/pubmed/7319858
301. Nakamura K, Mizowaki T, Imada H, Karasawa K, Uno T, Onishi H, Nihei K, Sasaki S, Ogura
M, Akimoto T. External-beam radiotherapy for localized or locally advanced prostate cancer
in Japan: a multi-institutional outcome analysis. Jpn J Clin Oncol 2008;38(3):200-4.
http://www.ncbi.nlm.nih.gov/pubmed/18304950
302. Pan CC, Kim KY, Taylor JM, McLaughlin PW, Sandler HM. Influence of 3D-CRT pelvic
irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J
Radiat Oncol Biol Phys 2002;53(5):1139-45.
http://www.ncbi.nlm.nih.gov/pubmed/12128113
303. Ploysongsang SS, Aron BS, Shehata WM. Radiation therapy in prostate cancer: whole pelvis
with prostate boost or small field to prostate? Urology 1992;40(1):18-26.
http://www.ncbi.nlm.nih.gov/pubmed/1621308
304. Rosen E, Cassady JR, Connolly J, Chaffey JT. Radiotherapy for prostate carcinoma: the JCRT
experience (1968-1978). II. Factors related to tumor control and complications. Int J Radiat
Oncol Biol Phys 1985;11(4):723-30. http://www.ncbi.nlm.nih.gov/pubmed/3980269
305. Seaward SA, Weinberg V, Lewis P, Leigh B, Phillips TL, Roach M, III. Improved freedom from
PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol
Phys 1998;42(5):1055-62. http://www.ncbi.nlm.nih.gov/pubmed/9869229
306. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the
prostate. An analysis of 551 patients treated with external beam radiation. Cancer
1987;60(7):1489-99. http://www.ncbi.nlm.nih.gov/pubmed/3113715
307. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen
K. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year
follow-up of a randomized controlled trial. BJU Int 2002;90(6):561-6.
http://www.ncbi.nlm.nih.gov/pubmed/12230618
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011